---
figid: PMC5217515__lctt-6-035Fig2
figtitle: Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell
  lung cancer
organisms:
- NA
pmcid: PMC5217515
filename: lctt-6-035Fig2.jpg
figlink: /pmc/articles/PMC5217515/figure/f2-lctt-6-035/
number: F2
caption: 'Inappropriate activation of the ALK pathway results in uncontrolled tumor
  growth and proliferation.Note: Ceritinib acts to inhibit phosphorylation of the
  EML4–ALK kinase domain, deactivating downstream growth pathways and inhibiting tumor
  proliferation.Abbreviations: ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated
  protein-like 4.'
papertitle: Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell
  lung cancer.
reftext: Mark W Burns, et al. Lung Cancer (Auckl). 2015;6:35-42.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9490644
figid_alias: PMC5217515__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
redirect_from: /figures/PMC5217515__F2
ndex: b6c34ece-deae-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5217515__lctt-6-035Fig2.html
  '@type': Dataset
  description: 'Inappropriate activation of the ALK pathway results in uncontrolled
    tumor growth and proliferation.Note: Ceritinib acts to inhibit phosphorylation
    of the EML4–ALK kinase domain, deactivating downstream growth pathways and inhibiting
    tumor proliferation.Abbreviations: ALK, anaplastic lymphoma kinase; EML4, echinoderm
    microtubule-associated protein-like 4.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Alk
  - pk
  - hop
  - bsk
  - ras
  - Ras64B
  - Ras85D
  - Akt
  - Stat92E
  - Erk7
  - rl
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Cancer
---
